Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.57), $0.11 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $2.36 million versus the consensus estimate of $4.01 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.